The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. NeoGenomics Inc. shares valued at $58,693 were sold by Bonello William on Mar 07. At $18.29 per share, Bonello William sold 3,209 shares. The insider’s holdings dropped to 98,516 shares worth approximately $1.64 million following the completion of this transaction.
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
As published in a research note from Needham on February 01, 2023, NeoGenomics Inc. [NEO] has been rated up from a Hold to a Buy and the price target has been revised to $15. This represents a -10.87% premium over Thursday’s closing price. Analysts at The Benchmark Company downgraded the stock from ‘”a Buy”‘ to ‘”a Hold”‘ outlook in a report released in late August. As of August 22, 2022, Needham has decreased its “Buy” rating to a “Hold” for NEO. Earlier on June 03, 2022, Piper Sandler initiated its rating. Their recommendation was “an Overweight” for NEO stock.
Analyzing NEO Stock Performance
On Thursday, NeoGenomics Inc. [NASDAQ: NEO] rose 24.57% to $16.63. The stock’s lowest price that day was $15.08, but it reached a high of $18.07 in the same session. During the last five days, there has been a surge of approximately 22.46%. Over the course of the year, NeoGenomics Inc. shares have jumped approximately 79.98%. Shares of the company reached a 52-week high of $18.07 on 02/23/23 and a 52-week low of $8.71 on 01/06/23. A 50-day SMA is recorded $11.34, while a 200-day SMA reached $9.76. Nevertheless, trading volume fell to 5.34 million shares from 1.27 million shares the previous day.
Support And Resistance Levels for NeoGenomics Inc. (NEO)
According to the 24-hour chart, there is a support level at 15.12, which, if violated, would cause prices to drop to 13.60. In the upper region, resistance lies at 18.11. The next price resistance is at 19.58. RSI (Relative Strength Index) is 76.19 on the 14-day chart, showing overbought technical sentiment. Moving Average Convergence Divergence (MACD) is at 1.29, which suggests the price will increase in the coming days. Percent R is at 21.43%, indicating bullish price movement. Stochastics %K at holding indicates that the stock is to be held.
Is NeoGenomics Inc. subject to short interest?
Stocks of NeoGenomics Inc. saw a sharp rise in short interest on Jan 12, 2023 jumping by 0.92 million shares to 4.43 million. Data from Yahoo Finance shows that the short interest on Dec 14, 2022 was 3.51 million shares. A jump of 20.77% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 4.25 of the overall float, the days-to-cover ratio (short ratio) jumped to 4.25.
Which companies own the most shares of NeoGenomics Inc. (NEO)?
According to BlackRock Fund Advisors filings, the company currently owns 20,128,563 shares, which is about 15.94% of the total NEO shares outstanding. The investor’s shares have appreciated by 992,453 from its previous 13-F filing of 19136110.0 shares. With the completion of the buy transaction, The Vanguard Group, Inc.’s stake is now worth $159,960,137. Brown Advisory LLC acquire a 3.67% interest valued at $76.08 million while Janus Henderson Investors US LLC purchased a 164,627 stake. A total of 432,774 shares of NeoGenomics Inc. were bought by SSgA Funds Management, Inc. during the quarter, and 348,026 were bought by T. Rowe Price Investment Manageme. In its current portfolio, Greenhouse Funds LLLP holds 2,795,231 shares valued at $33.21 million.
In terms of NeoGenomics Inc. share price expectations, FactSet research, analysts set an average price target of $20.33 in the next 12 months, up nearly 49.81% from the previous closing price of $13.35. Analysts anticipate NeoGenomics Inc. stock to reach $26.00 by 2023, with the lowest price target being $14.00. In spite of this, 9 analysts ranked NeoGenomics Inc. stock as an Overweight at the end of 2023. On March 29, 2022, Stephens assigned a price target of “an Equal-weight” to the stock and downgraded coverage with a $16.